# Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer

> **NCT01985893** · PHASE2 · WITHDRAWN · sponsor: **Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V.**

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Lapatinib plus trastuzumab

## Key facts

- **NCT ID:** NCT01985893
- **Lead sponsor:** Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-09
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to missing patient recruitment, the financial support was stopped.
- **Last updated:** 2016-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01985893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01985893, "Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01985893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*